⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LXRX News
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
globenewswire.com
LXRX
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
globenewswire.com
LXRX
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
globenewswire.com
LXRX
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
COLL
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
prnewswire.com
VTRS
LXRX
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
LXRX
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
globenewswire.com
LXRX
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
LXRX
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
globenewswire.com
LXRX